UnknownNot Applicable

Imaging Neuromelanin and Iron in Dystonia/Parkinsonism

80 participantsStarted 2018-07-01

Plain-language summary

To generate pilot data to investigate the potential to use in vivo iron- and neuromelanin-quantification as imaging tools for the diagnostic evaluation of movement disorders with predominant dystonia / parkinsonism. To this end we are planning to compare the MR imaging neuromelanin and iron-pattern and content in midbrain, striatum and further brain structures in clinically similar entities and respective, sex- and age-matched healthy controls.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinical diagnosis of parkinsonism and/or dystonia due to * dopa-responsive dystonia * sporadic or inherited/genetic dystonia * young-onset Parkinson's disease * NBIA * Mitochondrial disease * OR healthy controls * 18 to 60 years of age * able to give informed consent Exclusion Criteria: * Inability to tolerate 35min in an MRI machine * Participated in a clinical drug trial up to 28 days before inclusion into the present study * Contra-indications to 3T MRI on MRI safety grounds, such as presence of contra-indicated medical implants, as according to the established routine operating procedures for clinical MRI in the Lysholm Department of Neuroradiology at the National Hospital for Neurology and Neurosurgery.

What they're measuring

neuromelanin content

Timeframe: up to 8 weeks

Trial details

NCT IDNCT03572114

SponsorUniversity College, London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-07-01

Contact for this trial

Sebastian R Schreglmann, MD

0203448 8604 skgtsrs@ucl.ac.uk

View on ClinicalTrials.gov More Sporadic Dystonia trials